- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02329899
Standardisation of Investigations of Mild Bleeding Disorders (MBD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The working hypothesis of this prospective diagnostic study is that a standardised procedure in investigating patients with suspected MBD will lead to a better discrimination between patients with and without MBD and a more precise characterisation of MBD.
The primary objective of this diagnostic study is to evaluate the efficiency of a standardised procedure of MBD in children and adults referred to their respective outpatient clinics for bleeding symptoms. The following endpoints will be evaluated:
- The relative number of precise diagnosis (according to recognised classification of haemostatic disorders) in each clinical probability category;
- The number of biological tests performed per patient in each clinical probability category;
- The relative number of patients with no specialised investigations in the low risk group.
The secondary objective is to evaluate the bleeding events during a one-year follow-up. Follow-up will be performed with a phone call one year after the last consultation of the patient. The definition of a bleeding event will be any bleeding that promotes any specific medical attention (consultation, hospitalisation, transfusion, re-intervention in case of surgery). The detailed clinical history regarding each event will be collected. Bleeding events will be correlated to the clinical probability assessed at inclusion.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1205
- Haemostasis unit, University Hospitals of Geneva
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients aged more than two years-old referred by their physician (gynaecologist, paediatrician, general practitioner, surgeon, etc.) for investigations of a possible bleeding tendency will be included in this study. This prospective study will include consecutive patients attending the four outpatient clinics (Division of Angiology and Haemostasis and Paediatric Onco-Haematology Unit, University Hospitals of Geneva).
Exclusion Criteria:
- Pregnant women will be excluded because of modifications of the known modifications of the haemostasis system during pregnancy. Adult patients without discernment capacity will be excluded.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Possible MBD
Defined by:
In this group, the second step of investigations will be performed. |
Second step according to results of the first step:
|
MBD unlikely
Patients without criteria for possible MBD as listed above. In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation. |
Second step according to results of the first step:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative number of precise diagnosis
Time Frame: after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)
|
Diagnosis are going to be evaluated according to recognized classification of haemostatic disorders
|
after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)
|
Number of biological tests performed per patient
Time Frame: after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)
|
after the completion of the standardized diagnostic procedure (on average 6 weeks after enrollment)
|
|
Relative number of patients with no specialised investigations in the low risk group
Time Frame: after the completion of the standardized diagnostic procedure (on average 1 week after enrollment in this low risk group)
|
after the completion of the standardized diagnostic procedure (on average 1 week after enrollment in this low risk group)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of bleeding events
Time Frame: After one year follow-up
|
Phone call
|
After one year follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Boehlen Francoise, MD, Haemostasis unit, University Hospitals of Geneva, Switerland
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-246
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhagic Disorders
-
Ondrej HrdyRecruitingCoagulation and Hemorrhagic DisordersCzechia
-
Ludwig-Maximilians - University of MunichActive, not recruitingExtracorporeal Membrane Oxygenation Complication | Coagulation and Hemorrhagic DisordersGermany
-
University Hospital, AngersUnknownAnticoagulants; Circulating, Hemorrhagic DisorderFrance
-
French Defence Health ServiceInstitut de Recherche Biomedicale des Armees; Hôpital Edouard Herriot; Henri... and other collaboratorsCompleted
-
Gia Dinh People HospitalNot yet recruitingAnticoagulants; Circulating, Hemorrhagic Disorder
-
Vaderis Therapeutics AGRecruitingHereditary Hemorrhagic Telangiectasia (HHT)United States, Spain, France, Belgium, Netherlands, Italy
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaboratorsActive, not recruitingHereditary Hemorrhagic Telangiectasia (HHT)Canada
-
Imperial College LondonCompletedHereditary Hemorrhagic Telangiectasia (HHT)United Kingdom
-
Sunnybrook Health Sciences CentreCanadian Blood Services; National Blood Foundation; Canadian Department of National...CompletedHemorrhagic Shock | Trauma CoagulopathyCanada
-
University of PennsylvaniaCompletedHereditary Hemorrhagic Telangiectasia (HHT)United States
Clinical Trials on Second step of investigations
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Università degli Studi 'G. d'Annunzio' Chieti e...UnknownInfertility, Female | Fertility Disorders | Premature Ovarian FailureItaly
-
University of Illinois at Urbana-ChampaignCenters for Disease Control and PreventionUnknown
-
Reuth Rehabilitation HospitalCompletedAcquired Brain InjuryIsrael
-
The University of Hong KongRecruitingNeoplasms | Weight Management | Physical Symptom DistressHong Kong
-
Laboratorios Silanes S.A. de C.V.Completed
-
Keele UniversityUniversity College, London; University of Sheffield; Newcastle University; University... and other collaboratorsCompletedDementiaUnited Kingdom
-
University Hospital, Basel, SwitzerlandCompleted
-
University of TennesseeCompletedWeight LossUnited States
-
Centre Hospitalier Universitaire de BesanconSaint Anne's HospitalUnknown